Go online to PeerView.com/QDR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has brought substantial advances in the management of IBD. Nevertheless, under current therapeutic options, half of patients with moderate to severe ulcerative colitis (UC) or Crohn’s disease (CD) fail to achieve sustained remission. After years of IBD treatment dominated by monoclonal antibodies, we are currently witnessing promising developments of small molecules for UC and CD. Among them, Janus kinase (JAK) inhibitors are a promising new class that have demonstrated efficacy with a favorable safety profile in clinical trials. Utilizing a mix of didactic presentations and prerecorded patient videos, this activity based on a live symposium will explore current and emerging treatments and guidelines for UC and CD. The faculty panel provides a thorough examination of current and emerging JAK inhibitors, as well as insight into patient-centered, treat-to-target management approaches in IBD. Upon completion of this activity, participants should be better able to: Examine the burden of illness and unmet needs in patients with inflammatory bowel disease, Summarize efficacy and safety data related to current and emerging JAK inhibitors for the treatment of Crohn’s disease (CD) and ulcerative colitis (UC), Treat CD and UC in accordance with current evidence and guidelines, recognizing the role of non–anti-TNF therapies in inducing and maintaining remission in patients with moderate to severe disease, Incorporate JAK inhibitors into treatment plans for individual patients with CD or UC, recognizing the importance of achieving therapeutic targets and a patient-centered approach to care.
View all episodes
